Pulmonary Multidrug Resistant Tuberculosis Therapeutics
1. Sirturo patent expiration
Treatment: Treatment of pulmonary multi-drug resistant tuberculosis
SIRTURO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546428 | JANSSEN THERAP | Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Mar, 2029
(3 years from now) | |
| US7498343 | JANSSEN THERAP | Mycobacterial inhibitors |
Dec, 2026
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 28, 2019 |
| Orphan Drug Exclusivity(ODE-38) | Dec 28, 2019 |
| New Patient Population(NPP) | Aug 09, 2022 |
| ODE*(ODE*) | Aug 09, 2026 |
| Orphan Drug Exclusivity(ODE-251) | Aug 09, 2026 |
| Orphan Drug Exclusivity(ODE-307) | May 27, 2027 |
| M(M-306) | Jun 21, 2027 |
Drugs and Companies using BEDAQUILINE FUMARATE ingredient
NCE-1 date: 28 December, 2016
Market Authorisation Date: 27 May, 2020
Dosage: TABLET
More Information on Dosage
SIRTURO family patents
